What do medical sources say about Alprazolam (Xanax, Niravam) during pregnancy?

1st Trimester: MotherToBaby says most first-trimester alprazolam studies have not found more birth defects, though prescription records raised a heart-defect concern and cannot show whether the medicine was taken. Noh et al. reported a small class-level increase in heart defects after benzodiazepine prescriptions, while Fung et al. found no substantial overall increase or consistent pattern by defect type in a large 2026 U.S. cohort. For miscarriage, MotherToBaby says a large increase is unlikely, but Meng et al. and Picot et al. reported an association for benzodiazepines as a group, and EMA opened a review; its May 2026 recommendation said no action at that stage. MotherToBaby says suddenly stopping regular use can cause withdrawal, so any change calls for healthcare-provider discussion. Ask your provider about your situation. 2nd Trimester: MotherToBaby reports mixed alprazolam-specific findings on preterm birth and low birth weight. Li et al. and Yu et al. reported higher class-level preterm or growth-related risks after second-trimester exposure; Yu et al. combined benzodiazepines with related sleep medicines. Both studies used prescription records, do not show that medication was taken, and do not isolate alprazolam, so their results cannot establish a drug-specific cause. MotherToBaby says stopping regular use suddenly can cause withdrawal, and changes should be discussed with a healthcare provider. Ask your provider about your situation. 3rd Trimester: MotherToBaby says benzodiazepines, including alprazolam, can cause temporary newborn symptoms such as breathing trouble, low energy, poor feeding, or vomiting; not all babies have symptoms. The Xanax label says late use can cause newborn sedation or withdrawal and calls for monitoring after exposure during pregnancy or labor. MotherToBaby says alprazolam-specific research on later behavior or learning has not been done. Oh and Song reported an association between class-level exposure and later diagnoses, while Cho et al. found no overall increase after sibling control; neither study isolated alprazolam. Ask your provider about your situation.

What do medical sources say about Alprazolam (Xanax, Niravam) while breastfeeding?

MotherToBaby says alprazolam passes into milk and breastfeeding may be possible, though another medicine may be preferred; it advises watching for sleepiness, poor feeding, or poor weight gain. LactMed says repeated use is probably not the best choice, especially for a newborn or premature infant, while a single dose usually does not require a delay. The Xanax label says breastfeeding is not recommended during treatment, so the sources differ. Small milk studies show transfer, but published infant-effect reports and infant blood-level data are limited. Ask your provider about your situation.

Where do sources disagree on Alprazolam (Xanax, Niravam) in pregnancy or breastfeeding?

First-trimester birth-defect findings MotherToBaby says most alprazolam studies have not reported more birth defects. The Xanax label says observational benzodiazepine studies do not show a clear association with major birth defects, and the 2026 U.S. cohort found no substantial overall increase. The 2022 South Korean cohort found small class-level increases in overall and heart defects, and the 2019 U.S. case-control study found a few alprazolam-specific defect signals with small exposed counts. The studies used different populations and methods. Some grouped all benzodiazepines, while others analyzed individual drugs or rare defects. Prescription records may not show whether a medicine was taken, and rare outcomes can produce wide estimates. The large 2026 cohort did not find a substantial overall increase, but it did not provide an alprazolam-specific heart estimate. The earlier class-level and drug-specific signals are not consistent enough to identify a personal risk or a cause.

Back to search

Alprazolam

Medication

Xanax, Niravam

Benzodiazepine

Pregnancy

Birth defects: Noh et al. (2022) studied 3,094,227 South Korean pregnancies and found a small rise in major birth defects (adjusted RR 1.09) and heart defects (1.15) after first-trimester benzodiazepine prescriptions. The study included live-born infants, and a prescription does not prove that a medicine was taken. Tinker et al. (2019) used a case-control design in the National Birth Defects Prevention Study; alprazolam was linked with a few rare defects, but the exposed case counts were small and the confidence intervals were wide. Fung et al. (2026) analyzed two U.S. insurance cohorts: 2,478,434 Medicaid pregnancies and 1,750,721 MarketScan pregnancies. The pooled adjusted RR for any major malformation was 0.99 (95% CI 0.96 to 1.03); organ-specific increases did not appear consistently, and analyses of different benzodiazepines were similar. This study counted malformations present at birth and did not report a separate alprazolam heart-defect estimate in its abstract. Lee et al. (2022) followed 96 alprazolam-exposed and 629 unexposed pregnancies. It found no difference in congenital abnormalities, but reported associations with spontaneous abortion (OR 2.38) and low birth weight (OR 3.65); the exposed group was small and the authors noted possible confounding by the reason for treatment. Miscarriage: Meng et al. (2024) analyzed 3,067,122 pregnancies in Taiwan and found an association for benzodiazepines overall (OR 1.69) and for alprazolam (OR 1.39). Picot et al. (2026) pooled ten observational studies with more than 8,000 exposed pregnancies; the class-level OR was 1.68 (95% CI 1.48 to 1.90), and 1.58 (1.39 to 1.80) after adjustment for possible publication bias. The review reported an alprazolam pooled OR of 1.48 with substantial heterogeneity (I-squared 65%). Ishikawa et al. (2026) studied 44,118 miscarriage cases and 132,317 controls in Japan. The class-level adjusted OR was 1.241, while the alprazolam estimate was 0.853 (95% CI 0.707 to 1.030), which did not reach statistical significance. Li et al. (2026) analyzed 59,521 benzodiazepine-exposed and 394,956 unexposed pregnancies in Taiwan; the class-level RR for spontaneous abortion was 1.65 (95% CI 1.55 to 1.76). After accounting for competing events, the study found higher class-level risks of preterm birth (RR 1.20) and small for gestational age (RR 1.06), with more pronounced effects after second-trimester exposure. The abstract did not give trimester-specific effect sizes. Yu et al. (2025) analyzed 170,144 benzodiazepine receptor agonist users and 1,098,172 nonusers in Taiwan. The study combined benzodiazepines and Z-drugs, used prescription claims, and included only births at or after 20 weeks. Its second-trimester estimates included preterm birth OR 1.38 and small for gestational age OR 1.07. These observational class-level results do not establish that alprazolam caused an outcome. Child development: Oh and Song (2025) reported an association between prenatal benzodiazepine receptor agonist exposure and later neurodevelopmental diagnoses in South Korea. In a sibling analysis, the reported OR was 1.29 (95% CI 1.05 to 1.60) among 2,572 children. Cho et al. (2026) analyzed 3,809,949 live-born children in South Korea, including 94,482 exposed to benzodiazepines or Z-hypnotics. After sibling control, the overall psychiatric-disorder HR was 0.99 (95% CI 0.94 to 1.04), with no increase for individual diagnoses. Neither study provided an alprazolam-specific result.

Breastfeeding

Oo et al. (1995) measured alprazolam in milk from eight lactating women after a single 0.5 mg dose. Nursing was paused during the 36-hour sample period, so the study measured milk transfer rather than infant effects. LactMed reports that no relevant infant blood-level data were published by its 15 December 2025 revision. LactMed summarizes isolated reports of infant drowsiness, irritability, or withdrawal symptoms; its account of one drowsy infant among five exposed comes from a mixed medication follow-up study, so the alprazolam-specific subset is not visible in the abstract. Kelly et al. (2012) reported sedation in 2 of 124 infants exposed to benzodiazepines through milk; this was a class-level cohort, and one reported infant also had exposure to other central nervous system medicines. A Japanese case report measured alprazolam in milk while the mother used several medicines, so it cannot isolate alprazolam's effect. MotherToBaby and LactMed both describe sparse infant-effect information and say that a single dose usually does not require waiting before breastfeeding, while repeated use is treated more cautiously.

First-trimester birth-defect findings

Source A says: MotherToBaby says most alprazolam studies have not reported more birth defects. The Xanax label says observational benzodiazepine studies do not show a clear association with major birth defects, and the 2026 U.S. cohort found no substantial overall increase. (MotherToBaby: Alprazolam fact sheet, DailyMed: XANAX alprazolam tablet label, Fung et al., Annals of Internal Medicine 2026: Benzodiazepine use early in pregnancy and congenital malformations)
Source B says: The 2022 South Korean cohort found small class-level increases in overall and heart defects, and the 2019 U.S. case-control study found a few alprazolam-specific defect signals with small exposed counts. (Noh et al., PLoS Medicine 2022: First-trimester benzodiazepine cohort, Tinker et al., National Birth Defects Prevention Study 2019)
Why they differ: The studies used different populations and methods. Some grouped all benzodiazepines, while others analyzed individual drugs or rare defects. Prescription records may not show whether a medicine was taken, and rare outcomes can produce wide estimates.
What the evidence shows overall: The large 2026 cohort did not find a substantial overall increase, but it did not provide an alprazolam-specific heart estimate. The earlier class-level and drug-specific signals are not consistent enough to identify a personal risk or a cause.

Miscarriage after early-pregnancy benzodiazepine exposure

Source A says: MotherToBaby says a large increase in miscarriage risk from alprazolam is unlikely. Ishikawa et al. found an alprazolam-specific estimate that did not reach statistical significance. (MotherToBaby: Alprazolam fact sheet, Ishikawa et al., Archives of Women's Mental Health 2026: Benzodiazepines and miscarriage)
Source B says: Meng et al. reported an alprazolam-specific association. Picot et al. found an association for benzodiazepines as a group and an alprazolam pooled OR of 1.48. Li et al. also reported a class-level association with spontaneous abortion. (Meng et al., JAMA Psychiatry 2024: Benzodiazepine use and miscarriage, Picot et al., BMC Pregnancy and Childbirth 2026: Miscarriage meta-analysis, Li et al., JAMA Internal Medicine 2026: Pregnancy outcomes cohort)
Why they differ: The studies used different populations, exposure windows, comparison groups, and statistical methods. Class-level estimates combine medicines, while the alprazolam-specific results are less precise. All of the evidence is observational and may still be affected by the illness being treated or other factors.
Other sources: EMA PRAC minutes described a possible class-level miscarriage signal and requested a further review. Its May 2026 recommendation said no action at that stage. (EMA PRAC minutes, 4-7 May 2026, EMA PRAC recommendation on signals, 4-7 May 2026)
What the evidence shows overall: The newer class-level evidence is more concerning than the live summary suggests, but it does not establish that alprazolam causes miscarriage. Individual alprazolam findings conflict, and the regulator review had not produced a recommendation to change product information by the audit date.

Breastfeeding during alprazolam treatment

Source A says: The Xanax label says breastfeeding is not recommended during treatment because of possible serious infant effects, including sedation and withdrawal. (DailyMed: XANAX alprazolam tablet label)
Source B says: MotherToBaby says breastfeeding may be possible and LactMed says a single dose usually does not require waiting; both describe more caution for repeated use or possible infant symptoms. (MotherToBaby: Alprazolam fact sheet, LactMed (NIH): Alprazolam)
Why they differ: The product label takes a more restrictive position, while LactMed and MotherToBaby discuss the limited milk-transfer and infant-effect evidence and distinguish a single dose from repeated use.
What the evidence shows overall: The label is more restrictive than the two clinical summaries. LactMed and MotherToBaby also do not describe repeated alprazolam as a preferred option, and the infant-effect evidence remains limited.

Long-term child outcomes after prenatal benzodiazepine receptor agonist exposure

Source A says: Oh and Song reported an association with later neurodevelopmental diagnoses, including an association in a sibling analysis. (Oh and Song, British Journal of Psychiatry 2025: Child neurodevelopment cohort)
Source B says: Cho et al. found no overall increase in psychiatric diagnoses after sibling control and no increase for individual diagnoses. (Cho et al., BMJ 2026: Sibling-controlled psychiatric outcomes cohort)
Why they differ: The cohorts used different exposure definitions, outcomes, and analytic approaches. Both studied groups of benzodiazepines or related sleep medicines, and neither reported an alprazolam-specific estimate.
What the evidence shows overall: The class-level child-development evidence is unsettled. One study found an association, while the larger sibling-controlled study did not find an overall increase after accounting for shared family factors. These findings should not be presented as an alprazolam-specific result.

Last reviewed 2026-10-14

Independent check 2026-10-14

Not yet clinician-reviewed

Ask your provider about your situation.

Similar medications

Lorazepam
Oxazepam
Temazepam

Alprazolam

Alprazolam — Breastfeeding

What the research shows

What's in it / what was tested

Sources disagree

Options sources describe

Beyond pregnancy

All sources

Similar medications